Yizun Bio - About the company
Yizun Bio is a funded company based in Hangzhou (China), founded in 2018. It operates as a Provider of immune cell therapy solutions for treating solid tumors and autoimmune diseases. The company has 3343 active competitors, including 1141 funded and 806 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and Alexion.
Company Details
Provider of immune cell therapy solutions for treating solid tumors and autoimmune diseases. It focuses on creating disease specific therapies to enhance patient outcomes. It provide pipeline, including a notable IND application for a cell therapy targeting solid tumors.
- Website
- stphibio.com
- Email ID
- *****@stphibio.com
- Phone Number
- +86 **********
Key Metrics
Founded Year
2018
Location
Hangzhou, China
Stage
Funding Raised
Investors
Ranked
2986th among 3343 active competitors
Sign up to download Yizun Bio's company profile
Yizun Bio's funding and investors
Yizun Bio is a funded company. Yizun Bio has 1 institutional investor.
View details of Yizun Bio's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Yizun Bio's Competitors and alternates
Top competitors of Yizun Bio include Jazz Pharmaceuticals, Moderna and Alexion. Here is the list of Top 10 competitors of Yizun Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
3rd | Alexion 1992, Zurich (Switzerland), Acquired | Developer of therapies for patients with devastating and rare diseases | $133M | 79/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
5th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
6th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
8th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 73/100 | |
9th | _1548135965397.png?devicePixelRatio=2&height=30&width=30){kind=logo} Kronos Bio 2017, San Mateo (United States), Acquired | Developer of small molecule based therapeutics for cancer treatment | $271M | 72/100 | |
10th |  Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 72/100 | |
2986th | Provider of immune cell therapy solutions for treating solid tumors and autoimmune diseases | - | 22/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Yizun Bio's competitors? Click here to see the top ones
Yizun Bio's Investments and acquisitions
Yizun Bio has made no investments or acquisitions yet.
Reports related to Yizun Bio
Here is the latest report on Yizun Bio's sector:
Are you a Founder ?
FAQs about Yizun Bio
Explore our recently published companies
- Kedaletelematics - Unfunded company
- Golfwarehouseuk - 2006 founded, Unfunded company
- Alaskamillandfeed - 2003 founded, Acquired company
- Klimacorner - Germany based, Public company
- Pazit Infotech - 2025 founded, Unfunded company
- Sbsalaboratory Tech - Unfunded company
